Area of research
Hematology · Public Health, Environmental and Occupational Health
Research interest
Research interests include Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, Acute Lymphoblastic Leukemia research, and Chronic Lymphocytic Leukemia Research.
Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts
Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of <i>JAK2</i>-mutated post-MPN AML
Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia
Elevated B12 serum levels are associated with the presence of clonal hematopoiesis
RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax
Comprehensive characterization of IFNγ signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies
Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody–drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study
Single-cell systems pharmacology identifies development-driven drug response and combination therapy in B cell acute lymphoblastic leukemia
Impact of Age on Pharmacogenomics and Treatment Outcomes of B-Cell Acute Lymphoblastic Leukemia
Single-Cell Profiling of CD8+ T Cells in Acute Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal Hyperexpansion
IFNγ Signaling in Acute Myeloid Leukemia Mediates Immunomodulation and Reveals Therapeutic Strategies
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial
Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial
Impact of <i>F</i> <i>LT3</i> Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need
Application of precision medicine in clinical routine in haematology—Challenges and opportunities
Use of <scp>CYP3Ai</scp> and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the <scp>VIALE‐A</scp> study
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML
MDM2 inhibition: an important step forward in cancer therapy
Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies
Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells
Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow‐up from a phase 1b study
Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with <i>FLT3</i> Mutations
Preliminary Results of Balli-01: A Phase I Study of UCART22 (allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor) in Adult Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia
Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm